Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Pay attention here!!!

Mallinckrodt announced that it's buying Cadence for $1.3 billion.

The catalyst for the acquisition is painkiller Ofirmev, which was approved in 2010, but with roughly $100 million in trailing-12-month sales, it hasn't been a huge seller.

So Mallinckrodt paid $1.3 billion or 13 times sales for a poorly selling drug... so what would it pay for Rexista which will probably sell 3 to 6 times as much... $4 Billion to $8 Billion???

20K shares today makes you a millionaire in 3 to 5 years!!!